Skip to main content

Advertisement

SpringerLink
Log in

Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Post-transplant cytomegalovirus (CMV) disease can be almost completely avoided by current infection control procedures. However, CMV reactivation occurs in more than half of patients, and some patients can develop clinically resistant CMV infections. Whether resistance is due to the host’s immune status or a viral resistance mutation is challenging to confirm. Therefore, a prospective observational analysis of refractory CMV infection was conducted in 199 consecutive patients who received allogeneic hematopoietic stem cell transplantation at a single institution. Among them, 143 (72%) patients received anti-CMV drugs due to CMV reactivation, and only 17 (8.5%) exhibited refractory CMV infection. These patients had clinically refractory infection. However, viral genome analysis revealed that only one patient exhibited a mutation associated with the anti-CMV drug resistance. Clinical resistance was mainly correlated with host immune factors, and the incidence of resistance caused by gene mutations was low at the early stage after a transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am. 2010;24(2):319–37.

    Article  PubMed  Google Scholar 

  2. Ljungman P, de la Camara R, Cordonnier C, Einsele H, Engelhard D, Reusser P, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008;42(4):227–40.

    Article  CAS  PubMed  Google Scholar 

  3. Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–72.

    Article  PubMed  Google Scholar 

  4. Boeckh M, Ljungman P. How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Boeckh M, Murphy WJ, Peggs KS. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant. 2015;21(1):24–9.

    Article  CAS  PubMed  Google Scholar 

  6. Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119–27.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–92.

    Article  CAS  PubMed  Google Scholar 

  8. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227–36.

    Article  CAS  PubMed  Google Scholar 

  9. Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):369–81.

    Article  CAS  PubMed  Google Scholar 

  10. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–44.

    Article  CAS  PubMed  Google Scholar 

  11. Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the japan society for hematopoietic cell transplantation transplantation-related complication working group. Biol Blood Marrow Transplant. 2015;21(11):2008–16.

    Article  PubMed  Google Scholar 

  12. Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128(23):2624–36.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689–712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Drew WL. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis. 2010;50(5):733–6.

    Article  CAS  PubMed  Google Scholar 

  16. Chang YJ, Wang Y, Mo XD, Zhang XH, Xu LP, Yan CH, et al. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial. Cancer. 2017;123(15):2881–92.

    Article  CAS  PubMed  Google Scholar 

  17. Mardani M, Abolghasemi S, Shabani S, Tavakoli F, Saeedi A, Parkhideh S, et al. The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Iran J Microbiol. 2020;12(6):636–43.

    PubMed  PubMed Central  Google Scholar 

  18. Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, et al. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2008;14(11):1288–97.

    Article  CAS  PubMed  Google Scholar 

  19. Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, et al. Cytomegalovirus viremia, disease, and impact on relapse in T cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica. 2016;101(11):e465–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Walker CM, van Burik JA, De For TE, Weisdorf DJ. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant. 2007;13(9):1106–15.

    Article  PubMed  Google Scholar 

  21. Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol. 2005;77(3):425–9.

    Article  CAS  PubMed  Google Scholar 

  22. Cihlar T, Fuller MD, Mulato AS, Cherrington JM. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology. 1998;248(2):382–93.

    Article  CAS  PubMed  Google Scholar 

  23. Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV retinitis and viral resistance study group. J Infect Dis. 1998;177(3):770–3.

    Article  CAS  PubMed  Google Scholar 

  24. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis. 2001;184(12):1598–602.

    Article  CAS  PubMed  Google Scholar 

  25. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356(9230):645–9.

    Article  CAS  PubMed  Google Scholar 

  26. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300(4):413–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. van der Beek MT, Marijt EW, Vossen AC, van der Blij-de Brouwer CS, Wolterbeek R, Halkes CJ, et al. Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients. Antivir Ther. 2012;17(1):45–51.

    Article  PubMed  Google Scholar 

  28. Choi SH, Hwang JY, Park KS, Kim Y, Lee SH, Yoo KH, et al. The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations. Transpl Infect Dis. 2014;16(6):919–29.

    Article  CAS  PubMed  Google Scholar 

  29. Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother. 2009;63(3):600–8.

    Article  CAS  PubMed  Google Scholar 

  30. Kim YJ, Boeckh M, Cook L, Stempel H, Jerome KR, Boucek R Jr, et al. Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients. Transpl Infect Dis. 2012;14(6):611–7.

    Article  CAS  PubMed  Google Scholar 

  31. Shmueli E, Or R, Shapira MY, Resnick IB, Caplan O, Bdolah-Abram T, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis. 2014;209(4):557–61.

    Article  PubMed  Google Scholar 

  32. Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010;65(12):2628–40.

    Article  CAS  PubMed  Google Scholar 

  33. Gondo H, Minematsu T, Harada M, Akashi K, Hayashi S, Taniguchi S, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol. 1994;86(1):130–7.

    Article  CAS  PubMed  Google Scholar 

  34. Takenaka K, Gondo H, Tanimoto K, Nagafuji K, Fujisaki T, Mizuno S, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka bone marrow transplantation group. Bone Marrow Transplant. 1997;19(3):241–8.

    Article  CAS  PubMed  Google Scholar 

  35. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094–7.

    Article  PubMed  Google Scholar 

  36. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.

    Article  CAS  PubMed  Google Scholar 

  37. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9(9):543–58.

    Article  PubMed  Google Scholar 

  38. Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol. 1998;72(7):5927–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mousavi-Jazi M, Schloss L, Drew WL, Linde A, Miner RC, Harmenberg J, et al. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J Clin Virol. 2001;23(1–2):1–15.

    Article  CAS  PubMed  Google Scholar 

  40. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185(1):20–7.

    Article  CAS  PubMed  Google Scholar 

  41. de la Camara R. CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8(1):e2016031.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by JSPS KAKENHI (Grant No: 18H02840).

Author information

Authors and Affiliations

  1. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, 812-8582, Japan

    Fumiaki Jinnouchi, Yasuo Mori, Goichi Yoshimoto, Takuji Yamauchi, Takuya Nunomura, Ayano Yurino, Masayasu Hayashi, Junichiro Yuda, Takahiro Shima, Jun Odawara, Shuichiro Takashima, Kenjiro Kamezaki, Koji Kato, Toshihiro Miyamoto & Koichi Akashi

  2. Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan

    Katsuto Takenaka

Authors
  1. Fumiaki Jinnouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuo Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Goichi Yoshimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takuji Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuya Nunomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ayano Yurino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masayasu Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Junichiro Yuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takahiro Shima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jun Odawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shuichiro Takashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kenjiro Kamezaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Koji Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Toshihiro Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Koichi Akashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Katsuto Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FJ and KT designed the study, performed the statistical analyses, wrote the manuscript, and collected the patient data. YM, GY, TY, TN, AY, MH, JY, SD, TS, JO, ST, KK, KK, TM and KA collected the patient data. All the authors analyzed and reviewed the data and approved the final version of the manuscript.

Corresponding author

Correspondence to Katsuto Takenaka.

Ethics declarations

Conflict of interest

The authors have no financial interests to disclose. The authors declare no competing financial interests in relation to this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

12185_2021_3218_MOESM1_ESM.pdf

Supplementary Figure 1 (PDF 111 KB) Maps of the UL54 and UL97 genes and amplified lesions. Red bars represent confirmed mutations associated with drug resistance (14). Four primer pairs were designed for the UL54 gene and two pairs for the UL97 gene. The arrows indicate the position and direction of the primers.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jinnouchi, F., Mori, Y., Yoshimoto, G. et al. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Int J Hematol 115, 96–106 (2022). https://doi.org/10.1007/s12185-021-03218-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-021-03218-3

Keywords

Search

Navigation